References
- Cacheux W, Boisserie T, Staudacher L, et al (2008). Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol, 19, 1651-61.
- Grothey A, Sugrue MM, Purdie DM, et al (2008). Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 26, 5326-34. https://doi.org/10.1200/JCO.2008.16.3212
- Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
- Tripathy D, Slamon DJ, Cobleigh M, et al (2004). Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol, 22, 1063-70. https://doi.org/10.1200/JCO.2004.06.557
- Zuniga RM, Torcuator R, Jain R, et al (2010). Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol , 99, 237-42 . https://doi.org/10.1007/s11060-010-0121-0